CureVac NV (CureVac NV) 3-Year Revenue Growth Rate : -16.20% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV 3-Year Revenue Growth Rate?

CureVac NV's Revenue per Share for the three months ended in Dec. 2023 was $0.11.

During the past 12 months, CureVac NV's average Revenue per Share Growth Rate was -29.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -16.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 32.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 6 years, the highest 3-Year average Revenue per Share Growth Rate of CureVac NV was 96.10% per year. The lowest was -16.20% per year. And the median was 50.90% per year.

Competitive Comparison of CureVac NV's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, CureVac NV's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where CureVac NV's 3-Year Revenue Growth Rate falls into.

CureVac NV 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

CureVac NV (NAS:CVAC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

CureVac NV 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of CureVac NV's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.